SpringWorks Therapeutics Inc

SpringWorks Therapeutics — Corporate Update (November 2023)

24 slides from SpringWorks Therapeutics's corporate update, Nov 28, 2023

  1. Slide 1: FDA Approval Call November 27, 2023

    FDA Approval Call November 27, 2023

  2. Slide 2: Forward-looking statements note

    2 Note: Unless otherwise indicated, the information presented herein is as of November 27, 2023. This presentation may contain “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, relating to our business, operations, and financial co

  3. Slide 3: Today's Speakers and Agenda

    3 Today’s Speakers and Agenda Sections Presenter Opening Remarks Saqib Islam Chief Executive Officer U.S. Prescribing Information Jim Cassidy, MD, PhD Chief Medical Officer U.S. Launch Plans for OGSIVEO Bhavesh Ashar Chief Commercial Officer Closing Remarks Saqib Islam Chief Executive Officer Q&A Al

  4. Slide 4: Opening Remarks

    Opening Remarks Saqib Islam Chief Executive Officer

  5. Slide 5: First and Only FDA Approved Therapy for Adult Patients With Desmoid Tumors

    5 First and Only FDA Approved Therapy for Adult Patients With Desmoid Tumors 5

  6. Slide 6: Desmoid Tumor Patients Have Been Waiting for a Safe and Effective Therapy

    6 Desmoid Tumor Patients Have Been Waiting for a Safe and Effective Therapy Aggressive, invasive and highly debilitating soft - tissue tumors Can cause severe and chronic pain, loss of physical functioning and disfigurement Off - label systemic treatments are often poorly tolerated with limited effi

  7. Slide 7: OGSIVEO Can Address the Needs of Desmoid Tumor Patients at All Stages

    7 ~1,000 - 1,650 new patients diagnosed annually Incidence of 3 – 5 per million per year (1 - 3) with over 90% of patients receiving active intervention over the course of their disease OGSIVEO Can Address the Needs of Desmoid Tumor Patients at All Stages of Treatment Sources: SWTX Primary Research;

  8. Slide 8: Delivering the First FDA-Approved Therapy for Patients With Desmoid Tumors

    8 Broad label that enables patients at every stage of their treatment journey to be eligible for OGSIVEO Delivering the First FDA - Approved Therapy for Patients With Desmoid Tumors Joe Andrea Dana Significantly reduces disease progression and tumor size while addressing pain and other debilitating

  9. Slide 9: U.S. Prescribing Information

    U.S. Prescribing Information Jim Cassidy, MD, PhD Chief Medical Officer

  10. Slide 10: OGSIVEO U.S. Prescribing Information Overview

    10 OGSIVEO U.S. Prescribing Information Overview Full prescribing information is available at www.OGSIVEO.com. FIRST AND ONLY FDA - APPROVED THERAPY FOR DESMOID TUMOR PATIENTS INDICATION OGSIVEO is a gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require s

  11. Slide 11: Efficacy Summary From OGSIVEO Prescribing Information

    11 Efficacy Summary From OGSIVEO Prescribing Information Full prescribing information is available at www.OGSIVEO.com. Note: CI: confidence interval; ORR: objective response rate; CR: complete response; PR: partial response; NR: not reached. a) Assessed by blinded independent central review. b) Obta

  12. Slide 12: Safety Summary From OGSIVEO Prescribing Information

    12 Safety Summary From OGSIVEO Prescribing Information Full prescribing information is available at www.OGSIVEO.com. (1) Reported in over 15% of patients. Warnings and Precautions ▪ Diarrhea, ovarian toxicity, hepatotoxicity, non - melanoma skin cancers, electrolyte abnormalities, embryo - fetal tox

  13. Slide 13: U.S. Launch Plans for OGSIVEO

    U.S. Launch Plans for OGSIVEO Bhavesh Ashar Chief Commercial Officer

  14. Slide 14: Foundation in Place for OGSIVEO to Become the Standard of Care

    14 Foundation in Place for OGSIVEO to Become the Standard of Care Source: SWTX Primary Research, 2Q22; aided awareness. Motivated patient population Favorable shifts in market dynamics First and only approved therapy Physician enthusiasm and familiarity SARC Center participation in DeFi trial Stated

  15. Slide 15: Strategic Imperatives For OGSIVEO Launch

    15 Strategic Imperatives For OGSIVEO Launch EXPAND Educate physicians and patients to broaden the role of systemic therapy ADOPT Position OGSIVEO as first or next systemic treatment and standard of care SUPPORT Provide comprehensive patient support to help maximize patient access and adherence LEAD

  16. Slide 16: Targeted Launch Strategy With a Highly Experienced Field Team

    16 ‒ Regional Business Managers ‒ Thought Leader Liaisons ‒ Field Access Managers ‒ Nurse Advocates ‒ National Account Directors ‒ Medical Science Liaisons 35 Territory Business Managers supported by: Targeted Launch Strategy With a Highly Experienced Field Team Position OGSIVEO as first or next sys

  17. Slide 17: Transformative Clinical Benefit to Patients

    17 Transformative Clinical Benefit to Patients First and Only FDA - Approved Therapy Aggressive and Debilitating Rare Disease Ongoing Commitment to the Desmoid Tumor Community A Compelling Value Proposition for Stakeholders Our objective is that every appropriate patient who can benefit from OGSIVEO

  18. Slide 18: Robust and Tailored Patient Support and Access Program

    18 Robust and Tailored Patient Support and Access Program Financial Assistance Financial support for eligible patients, including co - pay program and Patient Assistance Program Coverage and Access Support Resources to facilitate reimbursement and timely and appropriate access to OGSIVEO Personalize

  19. Slide 19: Patient testimonial: Stephanie

    My tumor grew while on oral chemotherapy. I was switched to IV chemo, which shrank my tumor, but I had such bad side - effects that I had to take a break. My latest MRI shows that my tumor is stable, but it is pushing on my tailbone and causing excruciating pain. I am taking heavy duty pain medicati

  20. Slide 20: Closing Remarks

    Closing Remarks Saqib Islam Chief Executive Officer

  21. Slide 21: Rapidly Transitioning Into a Commercial-Stage Company

    21 21 Rapidly Transitioning Into a Commercial - Stage Company With Multiple Potential Value Drivers U.S. approval of OGSIVEO represents the first and only approved treatment for desmoid tumors, with data supporting a potentially practice - changing therapeutic profile for patients and meaningful com

  22. Slide 22: Thank You

    PATIENTS HAVE BEEN WAITING FOR ANSWERS. T’S GO Thank You &Y SpringWorks: THERAPEUTICS

  23. Slide 23: Q&A

    23 Badreddin Edris, PhD Chief Operating Officer Jim Cassidy, MD, PhD Chief Medical Officer Bhavesh Ashar Chief Commercial Officer Q&A Saqib Islam Chief Executive Officer

  24. Slide 24: SpringWorks Therapeutics

    2 SpringWorks' THERAPEUTICS

SpringWorks Therapeutics — Corporate Update (November 2023) on 6ix